Concentration and bioavailability of ciprofloxacin and teicoplanin in the Cornea

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 7, 2009, Pages 3176-3184

  Kaye, Stephen B ^a,b   Neal, Timothy ^a   Nicholson, Steven ^b   Szkurlat, Jagoda ^b   Bamber, Sharon ^a   Baddon, Andrew C ^b   Anderson, Sarah ^b   Seddon, Keeley ^a   Dwyer, Nichola ^a   Lovering, Andrew M ^c   Smith, Godfrey ^a  

^a Department of Medical Microbiology ^*  (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^c NORTH BRISTOL NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; TEICOPLANIN; ANTIINFECTIVE AGENT;

ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; AQUEOUS SOLUTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORNEA ENDOTHELIUM; CORNEA EPITHELIUM; DRUG BIOAVAILABILITY; DRUG CORNEA LEVEL; DRUG PENETRATION; DRUG TISSUE LEVEL; ESCHERICHIA COLI; HUMAN; HUMAN TISSUE; NONHUMAN; PENETRATING KERATOPLASTY; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; SWINE; TEAR FILM; ANIMAL; AQUEOUS HUMOR; BIOAVAILABILITY; CORNEA; CORNEA DISEASE; DRUG EFFECT; FLUORESCENCE POLARIZATION IMMUNOASSAY; METABOLISM; MICROBIOLOGICAL EXAMINATION;

ANIMALS; ANTI-BACTERIAL AGENTS; AQUEOUS HUMOR; BIOLOGICAL AVAILABILITY; CIPROFLOXACIN; CORNEA; CORNEAL DISEASES; ESCHERICHIA COLI; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMANS; KERATOPLASTY, PENETRATING; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS; SWINE; TEICOPLANIN;

EID: 67649980244     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-3201     Document Type: Article

References (51)

1. Benson H. Permeability of the cornea to topically applied drugs. Arch Ophthalmol. 1974;91:313-327.
2. Bouchard CS, King KK, Holmes JM. The kinetics of anterior chamber ofloxacin penetration. Cornea. 1996;15:72-75.
3. Burnstein NI, Anderson JA. Corneal penetration and ocular bioavailability of drugs. J Ocular Pharmacol. 1985;1:309-326.
4. Cutarelli PE, Lazarus HM, Jacobs MR, Lass JH. Antimicrobial activity and in vitro corneal epithelial toxicity of antimicrobial agents for gram-positive corneal pathogens. Curr Eye Res. 1993;12:603-608.
5. Frangie JP. Clinical Pharmacokinetics of various topical ophthalmic delivery systems. Clin Pharmacokinetics. 1995;29:130-138.
6. Huang AJ, Tseng SC, Kenyon KR. Paracellular permeability of corneal and conjunctival epithelia. Invest Ophthalmol Vis Sci. 1989;30(4):684-689.
7. Maurice D. The permeability of the rabbit corneal epithelium and endothelium to mannitol (letter). Invest Ophthalmol Vis Sci. 1991; 32(7):2163-2166.
8. Kishida K, Otori T. Quantitative study on the relationship of transcorneal permeability of drugs and their hydrophobicity. Jpn J Ophthalmol. 1980;24:251-259.
9. Mishina S. Clinical pharmacokinetics of the eye. Invest Ophthalmol Vis Sci. 1981;21:504-541.
10. Shell JW. Pharmacokinetics of topically applied ophthalmic drugs. Surv Ophthalmol. 1982;26:207-218.
11. Swan KC, White NG. Corneal permeability. Factors affecting penetration of drugs into the cornea. Am J Ophthalmol. 1942;25: 1043-1058.
12. Price FW Jr, Whitson WE, Collins KS, Gonzales JS. Corneal tissue levels of topically applied ciprofloxacin. Cornea. 1995;14:152-156.
13. McDermott ML, Tran TD, Cowden JW, Buggé CJ. Corneal stromal penetration of topical ciprofloxacin in humans. Ophthalmology. 1993;100(2):197-200.
14. Donnenfeld ED, Schrier A, Perry HD, Aulicino T, Gombert ME, Snyder R. Penetration of topically applied ciprofloxacin, norfloxacin and ofloxacin into the aqueous humor. Ophthalmology. 1994; 101(5):902-905.
15. Kim DH, Stark WJ, O'Brien TP, Dick JD. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. Ophthalmology. 2005;112(11):1992-1996.
16. Engel LS, Callegan MC, Hill JM, O'Callaghan RJ. Bioassays for quantitating ciprofloxacin and tobramycin in aqueous humor. J Ocul Pharmacol. 1993;9:311-320.
17. Donnenfeld ED, Perry HD, Snyder RW, Moadel R, Elsky M, Jones H. Intracorneal, aqueous humor, and vitreous humor penetration of topical and oral ofloxacin. Arch Ophthalmol. 1997;115(2):173-176.
18. Yalvac IS, Basci NE, Bozkurt A, Duman S. Penetration of topically applied ciprofloxacin and ofloxacin into the aqueous humor and vitreous. J Cataract Refract Surg. 2003;29(3):487-491.
19. Cahane M, Ben-Simon GJ, Barequet IS, et al. Human corneal stromal tissue concentration after consecutive doses of topically applied 3.3% vancomycin. Br J Ophthalmol. 2004;88:22-24.
20. Bailey EM, Rybak MJ, Kaatz GW. Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin. Antimicrob Agents Chemother. 1991;35:1089-1092.
21. Smith A, Pennefather PM, Kaye SB, Hart CA. Fluoroquinolones: place in ocular therapy. Drugs. 2001;61:747-761.
22. Bower K, Kowalski R, Gordon YJ. Fluoroquinolones in the treatment of bacterial keratitis. Am J Ophthalmol. 1996;121:712-715.
23. Leibowitz HM. Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis. Am J Ophthalmol. 1991;112(suppl 4):29S-33S.
24. Diamond JP, White L, Leeming JP, Bing Hoh H, Easty DL. Topical 0.3% ciprofloxacin, norfloxacin, and ofloxacin in treatment of bacterial keratitis: a new method for comparative evaluation of ocular drug penetration. Br J Ophthalmol. 1995;79(6):606-609.
25. Hyndiuk RA, Eiferman RA, Caldwell DR, et al. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycincefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group. Ophthalmology. 1996;103(11):1854-1863.
26. Pegues DA, Colby C, Hibberd PL. The epidemiology of resistance to ofloxacin and oxacillin among clinical coagulase-negative staphyloccocal isolates: analysis of risk factors and strain types. Clin Infect Dis. 1998;26:72-79.
27. Pinna A, Zanetti S, Sotgiu M, Sechi LA, Fadda G, Carta F. Identification and antibiotic susceptibility of coagulase negative staphylococci isolated in corneal/external infections. Br J Ophthalmol. 1999;83:771-773.
28. Sechi LA, Pinna A, Pusceddu C, Fadda G, Carta F, Zanetti S. Molecular characterization and antibiotic susceptibilities of ocular isolates of Staphylococcus epidermidis. J Clin Microbiol. 1999;37: 3031-3033.
29. Schlech BA, Alfonso E. Overview of the potency of moxifloxacin ophthalmic solution 0.5%. Survey Ophthalmol. 2005;50(suppl 1): S7-S15.
30. Park SH, Lim JA, Choi JS, Kim KA, Joo CK. The resistance patterns of normal ocular bacterial flora to 4 fluoroquinolone antibiotics. Cornea. 2009;28(1):68-72.
31. Miller D, Flynn PM, Scott IU, Alfonso EC, Flynn HW Jr. In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates. Arch Ophthalmol. 2006 Apr;124(4):479-483.
32. Moshirfar M, Mirzaian G, Feiz V, Kang PC. Fourth-generation fluoroquinolone-resistant bacterial keratitis after refractive surgery. J Cataract Refract Surg. 2006;32(3):515-518.
33. Rau G, Seedor JA, Shah MK, Ritterband DC, Koplin RS. Incidence and clinical characteristics of enterococcus keratitis. Cornea. 2008;27(8):895-899.
34. Feiz V, Redline DE. Infectious scleritis after pars plana vitrectomy because of methicillin-resistant Staphylococcus aureus resistant to fourth-generation fluoroquinolones. Cornea. 2007;26(2):238-240.
35. Micek ST. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2007;45(suppl 3):S184-S190.
36. Bains HS, Weinberg DV, Feder RS, Noskin GA. Postoperative vancomycin-resistant Enterococcus faecium endophthalmitis. Arch Ophthalmol. 2007;125(9):1292-1293.
37. Green M, Apel A, Stapleton F. Risk factors and causative organisms in microbial keratitis. Cornea. 2008;27(1):22-27.
38. Ly CN, Pham JN, Badenoch PR, et al. Bacteria commonly isolated from keratitis specimens retain antibiotic susceptibility to fluoroquinolones and gentamicin plus cephalothin. Clin Exp Ophthalmol. 2006;34(1):3-5.
39. Dollery C, ed. Therapeutic Drugs. 2nd ed. Edinburgh: Churchill Livingstone; 1999:230-234.
40. Andrews JM, BSAC Working Party on Susceptibility Testing. BSAC standardized disc susceptibility testing method. J Antimicrob Chemother. 2001;48;(suppl 1):43-57.
41. Sasaki H, Yamamura K, Mukai T, et al. Modification of ocular permeability of peptide drugs by absorption promoters. Biol Pharm Bull. 2000;23(12):1524-1527.
42. Sasaki H, Ichikawa M, Yamamura K, Nishida K, Nakamura J. Ocular membrane permeability of hydrophilic drugs for ocular peptide delivery. J Pharm Pharmacol. 1997;49(2):135-139.
43. Bachman WG, Wilson G. Essential ions for maintenance of the corneal epithelial surface. Invest Ophthalmol Vis Sci. 1985;26: 1484-1488.
44. Martino P, Venditti M, Micozzi A. Teicoplanin in the treatment of Gram-positive bacterial endocarditis. Antimicrob Agents Chemother. 1989;33:1329-1333.
45. Tsakris A, Papadimitriou E, Douboyas J, Antoniadis A. Emergence of teicoplanin-resistant Staphylococcus haemolyticus clinical isolates in Greece. J Antimicrob Chemother. 2000;46(6):1040-1041.
46. Podder SK, Moy KC, Lee VH. Improving the safety of topically applied timolol in the pigmented rabbit through manipulation of formulation composition. Exp Eye Res. 1992;54(5):747-757.
47. Wilson AP. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet. 2000;39:167-183.
48. Felmingham D. Glycopeptides: vancomycin and teicoplanin. In: Reeves DS, Wise R, Andrews JM, White LO, eds. Clinical Antimicrobial Assays. Oxford, UK: Oxford University Press; 1999:137-148.
49. Wilson APR, Gruneberg RN, Neu H. A critical review of the dosage of teicoplanin in Europe and the USA. Int J Antimicrob Agents. 1994;4:S1-S30.
50. White LO, McMullin C, Davis AJ, MacGowan AP, Harding I, Reeves DS. The quality of clinical serum teicoplanin assays: an experimental European EQA distribution. J Antimicrob Chemother. 1996; 38(4):701-706.
51. Robertson SM, Curtis MA, Schlech BA, et al. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Surv Ophthalmol. 2005;50(suppl 1):S32-S45.